533 related articles for article (PubMed ID: 28176907)
1. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
3. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
Pepin JL; Cockcroft JR; Midwinter D; Sharma S; Rubin DB; Andreas S
Chest; 2014 Dec; 146(6):1521-1530. PubMed ID: 25058845
[TBL] [Abstract][Full Text] [Related]
4. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
7. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
8. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
9. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
Covelli H; Pek B; Schenkenberger I; Scott-Wilson C; Emmett A; Crim C
Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-daily fluticasone furoate/vilanterol
Maltais F; Schenkenberger I; Wielders PLML; Ortiz de Saracho J; Chinsky K; Watkins M; Millar V; Crim C
Ther Adv Respir Dis; 2020; 14():1753466620965145. PubMed ID: 33081606
[TBL] [Abstract][Full Text] [Related]
12. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
14. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
17. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
Rodrigo GJ; Neffen H
Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
Zheng J; de Guia T; Wang-Jairaj J; Newlands AH; Wang C; Crim C; Zhong N
Curr Med Res Opin; 2015 Jun; 31(6):1191-200. PubMed ID: 25830381
[TBL] [Abstract][Full Text] [Related]
19. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
